Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Clinical trial NCT01186861 · COMPLETED

Trial details

NCT number: NCT01186861
Sponsor: Astellas Pharma Inc
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Start date: 2011-03-04
Primary completion: 2013-07-01
Enrollment: 205

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.